FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma By Ogkologos - January 31, 2025 591 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CK-301-101 Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... November 20, 2024 FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma October 26, 2023 EMA Recommends Granting a Marketing Authorisation for Elinzanetant September 26, 2025 Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically... August 8, 2023 Load more HOT NEWS Bus Driver Wears Different Costume Each Day To Make Kids Smile... Reused, Reheated Cooking Oil May Trigger Breast Cancer Progression, Metastasis Bride Diagnosed with Stage IV Triple-Negative Breast Cancer 6 Months Before... 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with...
